Drug‐Eluting Stents vs Intracoronary Brachytherapy for In‐Stent Restenosis: A Meta‐Analysis

Lu, Yongguang; Chen, Yanmei; Li, Lang; Zhao, R Z; Fu, Chunhui; Hua, Yan

doi:10.1002/clc.20900

Cited by 12 publications

(5 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Restenosis after coronary surgery or angioplasty remains an issue that needs to be solved (6)(7)(8). In-stent restenosis (ISR) occurs in 15-50% of patients after bare-metal stent implantation and still constitutes one of the most common adverse events (9).…”

Section: Discussionmentioning

confidence: 99%

In vitro selection and identification of ssDNA aptamers recognizing the Ras protein

Wang

Mao

et al. 2014

Molecular Medicine Reports

View full text Add to dashboard Cite

The aim of this study was to develop high-affinity single-stranded DNA (ssDNA) aptamers that can selectively recognize the protein Ras and can be used as preventive and therapeutic agents for restenosis occurring after coronary surgery or angioplasty. For this purpose, we used the systematic evolution of ligands by exponential enrichment (SELEX) technique, also known as in vitro selection. Using this technique, ssDNA aptamers recognizing the Ras protein were obtained from a synthesized random ssDNA library in vitro. The binding rate and affinity of each aptamer pool, isolated in successive rounds of selection, were measured using ELISA, and the finally selected aptamer pool was cloned and sequenced. The binding affinities of each aptamer in this pool were measured. Their primary and secondary structures were analyzed using the DNAMAN 5.29 software, and the relationship between these structures and corresponding binding affinities was analyzed. The rate of aptamer pool binding to the Ras protein gradually increased from 2.4 to 34.5% along the selection process. Optical density (OD) and equilibrium dissociation constant (Kd) measurements showed that OD gradually increased from 0.220 to 1.080 and Kd decreased from 51.5 to 18.3 nM. The 11th pool of aptamers was selected based on these analyses, and cloning and sequencing of individual aptamers was performed. Secondary structure analysis revealed different conformations, but of a single type: stem‑loop. The aptamer Ra1 showed the highest affinity, with a measured OD of 1.213 and an estimated Kd of 15.3 nM. The binding affinity of the aptamer Ra1 to Ras was dose-dependent. In conclusion, high‑affinity ssDNA aptamers recognizing the Ras protein have been successfully selected. These aptamers may serve in the future as preventive and/or therapeutic agents for restenosis occurring after coronary surgery or angioplasty.

show abstract

Section: Discussionmentioning

confidence: 99%

In vitro selection and identification of ssDNA aptamers recognizing the Ras protein

Wang

Mao

et al. 2014

Molecular Medicine Reports

View full text Add to dashboard Cite

show abstract

“…Waksman et al described a significant reduction in neo-intimal formation in pig coronary arteries treated with gamma-irradiation ( 192 Ir) or betairradiation ( 90 SR/Y) prior to stent placement, 22 while Hehrlein et al were the first to use stents to deliver radiation in an animal re-stenosis model. 23 However, radiation therapy has now been superseded by the availability of drug-eluting stents (DES) 24 , the reasons for which are elucidated below.…”

Section: Pathophysiology Of In-stent Re-stenosismentioning

confidence: 99%

Impact of metabolic syndrome on re-stenosis development: Role of drug-eluting stents

Goyal

Bharti

Krishnamurthy

et al. 2012

Diabetes and Vascular Disease Research

View full text Add to dashboard Cite

Metabolic syndrome (MetS) is defined as a cluster of numerous cardiovascular risk factors, which encompasses obesity, dyslipidaemia, insulin resistance and hypertension. Patients with MetS are more prone to developing cardiovascular events than other patients. To date, several approaches such as physical exercise, dietary control and invasive and non-invasive therapeutic interventions for dyslipidaemia, hypertension and insulin resistance have been used to manage MetS. However, there is a progressive elevation in the incidence of fatal and non-fatal cardiovascular events due to the increased prevalence of obesity and diabetes. Percutaneous coronary intervention has emerged over the last few years as an effective revascularisation strategy for those with coronary artery disease, in parallel with the development of effective anti-platelet medications and newer drug-eluting stents. In recent years, considerable research efforts have been undertaken to elucidate the pathophysiology of re-stenosis and develop strategies to prevent re-stenosis following percutaneous transluminal coronary angioplasty and stent implantation. Although the rate of stent re-stenosis and target-lesion revascularisation has been reduced, there is little information in the literature on the outcome of MetS in the pathophysiology of re-stenosis. In this review article, we summarise the recent development and progress on re-stenosis and the role of drug-eluting stents, particularly in MetS.

show abstract

“…This phenomenon repeated itself with brachytherapy. No long-term benefit was seen in animal models but humans did benefit [263,[265][266][267][268][269]. Serruys et al state: "Finally, because the results of experiments in animal models cannot be directly translated to humans, specific clinical trials of safety and efficacy are required for each device [DES] [270].…”

Section: Palmaz Et Al First Employed Stents In Peripheral Arteries Imentioning

confidence: 99%

A Discussion of the Role of Complex Evolved Systems in the Development of Invasive Cardiovascular Interventions as Illustrated by the Blalock- Taussig Shunt and Intra-Arterial Stents

Greek¹

2014

Biol Syst Open Access

View full text Add to dashboard Cite

Scientific disciplines normally thought of as outside the sphere of medical science have experienced advances over the past twenty years that currently have profound implications for medical care and medical research. Evolutionary and developmental biology, complexity and chaos science, along with the Human Genome Project and spinoff projects, have dramatically altered our understanding of how the human body functions and what can be expected from research methods like animal modeling. In this article, I summarize these advances and examine one historical medical development, the Blalock-Taussig shunt, in order to ascertain whether historically accepted representations of this development are consistent with current knowledge. I also examine an ongoing technology-intra-arterial stent development-to compare human data to the known animal data and place this comparison in the context of the aforementioned advances.

show abstract

Drug‐Eluting Stents vs Intracoronary Brachytherapy for In‐Stent Restenosis: A Meta‐Analysis

Cited by 12 publications

References 35 publications

In vitro selection and identification of ssDNA aptamers recognizing the Ras protein

In vitro selection and identification of ssDNA aptamers recognizing the Ras protein

Impact of metabolic syndrome on re-stenosis development: Role of drug-eluting stents

A Discussion of the Role of Complex Evolved Systems in the Development of Invasive Cardiovascular Interventions as Illustrated by the Blalock- Taussig Shunt and Intra-Arterial Stents

Contact Info

Product

Resources

About